Eisai (ESAIY) and Biogen (BIIB) announced that the U.S. Food and Drug Administration, FDA, has approved the Supplemental Biologics License ...
U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...
The FDA has approved a Supplemental Biologics License Application (sBLA) for intravenous maintenance dosing of Eisai and Biogen’s Leqembi (lecanemab) once every four weeks for patients with early ...
AstraZeneca AZN and partner Daiichi Sankyo announced that the FDA has approved the supplemental biologics license application ...
INDICATION LEQEMBI ® [ (lecanemab-irmb) 100 mg/mL injection for intravenous use] is indicated for the treatment of Alzheimer’s disease (AD). Treatment with LEQEMBI should be initiated in patients with ...
Apitegromab has not been approved for any use by the FDA or any other regulatory agency. About the Phase 3 SAPPHIRE Trial SAPPHIRE was a randomized, double-blind, placebo-controlled Phase 3 ...
Journey Medical's future hinges on Emrosi, a new formulation of minocycline for rosacea, showing superior efficacy. Read why ...
Telehealth platforms like Motivated are changing how men treat ED with its fast, affordable, and discreet online service.
The Philippine Dermatological Society (PDS) has warned the public about the risks of intravenous (IV) glutathione following a ...
Any NYT reader looking at the buzzy front page headline below would immediately think that Robert F Kennedy Jr. is a madman.
NeurAxis offers FDA-cleared IB-Stim device for pediatric IBS pain. Despite positive advancements, market recognition lags.
Make an appointment to retake a written test. Pick up a previously approved permit, driver’s license, or identification. New Guam driver’s licenses and identification. Changing to a REAL ID.